North Immunology joins biotech reverse merger boom with Aethlon deal

North Immunology joins biotech reverse merger boom with Aethlon deal

Armed with $180 million and a dual-acting antibody for eczema, the startup is capitalizing on a change in sentiment that’s led to a sudden spike in reverse merger deals.

Aethlon Medical (AEMD) Stock Rockets 471% Following North Immunology Merger Announcement

Aethlon Medical (AEMD) stock jumped 471% after revealing merger with North Immunology, backed by $180M funding for atopic dermatitis drug development.

Aethlon Medical (AEMD) Stock Surges 471% on North Immunology Merger Deal

TLDR Aethlon Medical stock surged over 471% in premarket trading on September 17, 2026, after announcing a merger with North Immunology The all-stock deal will create a new Nasdaq-listed company called North Immunology, Inc., trading under the ticker NRTX North Immunology shareholders and PIPE...

Aethlon’s 467% Stock Rally Reflects a $16.5 Million Merger Stub, Not a $346.5 Million Windfall

Aethlon Medical shares traded at $8.105 at 9:43 a.m. Eastern on Thursday, up 466.78% from Wednesday’s $1.43 close after the company agreed to merge with privately held North Immunology. Volume had reached 56.3 million shares, about 43 times Nasdaq’s displayed average, and the session range already stretched from $7.5001 to $9.50. The percentage is spectacular…

Aethlon Medical and North Immunology Agree to Merger, Bringing Atopic Dermatitis Biotech to Nasdaq - Channelchek

Aethlon Medical and North Immunology have agreed to an all-stock reverse merger that will take North public, backed by a $180 million financing to advance its IL-13 x IL-18 bispecific antibody for atopic dermatitis.